- Abbott will spin off its nutrition unit, home to Similac, Pedialyte and Ensure, into a separate publicly traded company through a tax-free distribution to shareholders, expected to complete by the end of 2027. Daniel Salvadori becomes chief executive of the new company.
- Shares fell 4% in premarket trading, having already declined more than 18% this year. A decline on announcing a separation is unusual, since these transactions are typically received as value-releasing.
- The structure explains the reaction. A spin-off distributes the business to the same shareholders rather than selling it, so holders retain the exposure, in a smaller company without healthcare earnings to absorb litigation and recall costs.
- Those costs have been substantial and recent. Abbott agreed last month to pay $385 million to settle US allegations over poor manufacturing practices at two facilities, including one involving a contaminated plant producing powder infant formula, and $670 million in August to settle some lawsuits alleging it concealed the risk that its formula for premature infants can cause a deadly bowel disease. More than $1 billion in roughly two months, and the word “some” indicates further claims remain.
What Happened?
Abbott said the nutrition business would be better positioned to focus its resources more strategically as an independent company, and that the separation will not affect 2026 guidance or the 2027 guidance due in January. The move leaves medical devices, diagnostics and established drugs operating separately from nutrition and infant formula, which has had repeated problems including recalls that caused a nationwide shortage in 2022. Abbott lowered prices on some nutrition products at the end of last year to attract price-conscious consumers, having previously raised them to cover higher manufacturing costs. Rival Reckitt Benckiser has also sought to shed its Mead Johnson infant formula business.
Why It Matters?
Separation changes who bears the liability within a shareholder’s portfolio rather than removing it. In a sale, the risk transfers to a buyer and the seller receives cash. In a spin-off, the same investors hold both companies, and the question becomes which entity the obligations follow and what financial capacity it has. A standalone nutrition business carrying ongoing litigation over infant formula, without a large diversified healthcare parent behind it, is a materially different proposition from the same unit inside Abbott. The terms of the separation, specifically how liabilities and cash are allocated, are what shareholders should examine when published. The pricing reversal is the most informative operating detail. Raising prices to recover manufacturing costs and then cutting them to retain price-conscious buyers describes a company that discovered it has no pricing power in a staple category. Families trading down on infant formula is a serious consumer signal, and it sits alongside Federal Reserve data showing the highest share of households with debt payments above 40% of income since 2010 and consumer sentiment’s current conditions index at an all-time low. Two large manufacturers exiting the same category is a judgement about the business rather than about either company. Reckitt has pursued the same course with Mead Johnson, which suggests the combination of recall exposure, litigation and limited pricing power makes infant formula unattractive relative to the capital it absorbs. That has implications for supply, given a recall at one manufacturer caused a national shortage as recently as 2022.
What Next?
The separation terms are the disclosure that matters, particularly the allocation of litigation liabilities and the capital structure of the new company, and completion is not expected until the end of 2027. Abbott provides 2027 guidance in January. Watch whether further formula litigation is settled before the spin completes, since remaining claims would follow the new entity. For the category, two major manufacturers withdrawing raises questions about supply resilience that regulators may eventually address.
Affected Tickers and Coins: ABT, RKT
Source: Bloomberg
